|
1
|
Wong MC, Lam AT, Li DK, Lau JT, Griffiths
SM and Sung JJ: Factors associated with practice of colorectal
cancer screening among primary care physicians in a Chinese
population: A cross-sectional study. Cancer Epidemiol. 33:201–206.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Matsuoka K, Watanabe N and Nakamura K:
O-glycosylation of a precursor to a sweet potato vacuolar protein,
sporamin, expressed in tobacco cells. Plant J. 8:877–889. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Zheng R, Zeng H, Zhang S, Chen T and Chen
W: National estimates of cancer prevalence in China, 2011. Cancer
Lett. 370:33–38. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Wang XQ, Tang ZX, Yu D, Cui SJ, Jiang YH,
Zhang Q, Wang J, Yang PY and Liu F: Epithelial but not stromal
expression of collagen alpha-1(III) is a diagnostic and prognostic
indicator of colorectal carcinoma. Oncotarget. 7:8823–8838.
2016.PubMed/NCBI
|
|
6
|
Zhang ZJ, Zheng ZJ, Kan H, Song Y, Cui W,
Zhao G and Kip KE: Reduced risk of colorectal cancer with metformin
therapy in patients with type 2 diabetes: A meta-analysis. Diabetes
Care. 34:2323–2328. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zhong LL, Chen HY, Cho WC, Meng XM and
Tong Y: The efficacy of Chinese herbal medicine as an adjunctive
therapy for colorectal cancer: A systematic review and
meta-analysis. Complement Ther Med. 20:240–252. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kim HJ, Park J, Lee SK, Kim KR, Park KK
and Chung WY: Loss of RUNX3 expression promotes cancer-associated
bone destruction by regulating CCL5, CCL19 and CXCL11 in non-small
cell lung cancer. J Pathol. 237:520–531. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Estécio MR, Maddipoti S, Bueso-Ramos C,
DiNardo CD, Yang H, Wei Y, Kondo K, Fang Z, Stevenson W, Chang KS,
et al: RUNX3 promoter hypermethylation is frequent in leukaemia
cell lines and associated with acute myeloid leukaemia inv(16)
subtype. Br J Haematol. 169:344–351. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ku JL, Kang SB, Shin YK, Kang HC, Hong SH,
Kim IJ, Shin JH, Han IO and Park JG: Promoter hypermethylation
downregulates RUNX3 gene expression in colorectal cancer cell
lines. Oncogene. 23:6736–6742. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Calin GA, Sevignani C, Dumitru CD, Hyslop
T, Noch E, Yendamuri S, Shimizu M, Rattan S, Bullrich F, Negrini M,
et al: Human microRNA genes are frequently located at fragile sites
and genomic regions involved in cancers. Proc Natl Acad Sci USA.
101:2999–3004. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ambros V: The functions of animal
microRNAs. Nature. 431:350–355. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhang B, Pan X, Cobb GP and Anderson TA:
microRNAs as oncogenes and tumor suppressors. Dev Biol. 302:1–12.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Hu F, Min J, Cao X, Liu L, Ge Z, Hu J and
Li X: MiR-363-3p inhibits the epithelial-to-mesenchymal transition
and suppresses metastasis in colorectal cancer by targeting Sox4.
Biochem Biophys Res Commun. 474:35–42. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Favoriti P, Carbone G, Greco M, Pirozzi F,
Pirozzi RE and Corcione F: Worldwide burden of colorectal cancer: A
review. Updates Surg. 68:7–11. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Cohen SJ, Cohen RB and Meropol NJ:
Targeting signal transduction pathways in colorectal cancer - more
than skin deep. J Clin Oncol. 23:5374–5385. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Seymour MT, Maughan TS, Ledermann JA,
Topham C, James R, Gwyther SJ, Smith DB, Shepherd S, Maraveyas A,
Ferry DR, et al FOCUS Trial Investigators; National Cancer Research
Institute Colorectal Clinical Studies Group, : Different strategies
of sequential and combination chemotherapy for patients with poor
prognosis advanced colorectal cancer (MRC FOCUS): A randomised
controlled trial. Lancet. 370:143–152. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Croitoru ME, Cleary SP, Di Nicola N, Manno
M, Selander T, Aronson M, Redston M, Cotterchio M, Knight J, Gryfe
R, et al: Association between biallelic and monoallelic germline
MYH gene mutations and colorectal cancer risk. J Natl Cancer Inst.
96:1631–1634. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Soong R, Shah N, Peh BK, Chong PY, Ng SS,
Zeps N, Joseph D, Salto-Tellez M, Iacopetta B and Ito Y: The
expression of RUNX3 in colorectal cancer is associated with disease
stage and patient outcome. Br J Cancer. 100:676–679. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Tan SH, Ida H, Lau QC, Goh BC, Chieng WS,
Loh M and Ito Y: Detection of promoter hypermethylation in serum
samples of cancer patients by methylation-specific polymerase chain
reaction for tumour suppressor genes including RUNX3. Oncol Rep.
18:1225–1230. 2007.PubMed/NCBI
|
|
22
|
Smith E, De Young NJ, Pavey SJ, Hayward
NK, Nancarrow DJ, Whiteman DC, Smithers BM, Ruszkiewicz AR,
Clouston AD, Gotley DC, et al: Similarity of aberrant DNA
methylation in Barretts esophagus and esophageal adenocarcinoma.
Mol Cancer. 7:752008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Nishio M, Sakakura C, Nagata T, Komiyama
S, Miyashita A, Hamada T, Kuryu Y, Ikoma H, Kubota T, Kimura A, et
al: RUNX3 promoter methylation in colorectal cancer: Its
relationship with microsatellite instability and its suitability as
a novel serum tumor marker. Anticancer Res. 30:2673–2682.
2010.PubMed/NCBI
|
|
24
|
Kang KA, Kim KC, Bae SC and Hyun JW:
Oxidative stress induces proliferation of colorectal cancer cells
by inhibiting RUNX3 and activating the Akt signaling pathway. Int J
Oncol. 43:1511–1516. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Sun Q, Zhang J, Cao W, Wang X, Xu Q, Yan
M, Wu X and Chen W: Dysregulated miR-363 affects head and neck
cancer invasion and metastasis by targeting podoplanin. Int J
Biochem Cell Biol. 45:513–520. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Luo X, Burwinkel B, Tao S and Brenner H:
MicroRNA signatures: Novel biomarker for colorectal cancer? Cancer
Epidemiol Biomarkers Prev. 20:1272–1286. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Xu X, Wu X, Wu S, Jiang Q, Liu H, Chen R
and Sun Y: Study on miR-490-5p and miR-363 as novel biomarkers for
the diagnosis of colorectal cancer. Zhonghua Wei Chang Wai Ke Za
Zhi. 17:45–50. 2014.(In Chinese). PubMed/NCBI
|
|
28
|
Watanabe T, Kobunai T, Ikeuchi H, Yamamoto
Y, Matsuda K, Ishihara S, Nozawa K, Iinuma H, Kanazawa T, Tanaka T,
et al: RUNX3 copy number predicts the development of UC-associated
colorectal cancer. Int J Oncol. 38:201–207. 2011.PubMed/NCBI
|
|
29
|
Mu WP, Wang J, Niu Q, Shi N and Lian HF:
Clinical significance and association of RUNX3 hypermethylation
frequency with colorectal cancer: A meta-analysis. OncoTargets
Ther. 7:1237–1245. 2014. View Article : Google Scholar
|
|
30
|
Tsuji S, Kawasaki Y, Furukawa S, Taniue K,
Hayashi T, Okuno M, Hiyoshi M, Kitayama J and Akiyama T: The
miR-363-GATA6-Lgr5 pathway is critical for colorectal
tumourigenesis. Nat Commun. 5:31502014. View Article : Google Scholar : PubMed/NCBI
|
